Michael Lyman
Michael Lyman is the Vice President of Discovery Research at IconOVir Bio. Prior to joining IconOVir, Michael was the Director of Translational Research at the Salk Institute of Biological Studies where he led a translational research team working with Clodagh O’Shea to develop a pipeline of novel virus-based therapies including oncolytic viruses. Before going to the […]
Heba Nowyhed, Ph.D.
Heba Nowyhed is the Chief Scientific Officer at IconOVir Bio. She joined IconOVir from Vida Ventures, where she was a Senior Associate conducting scientific due diligence on investment opportunities in the Biotech space, and supporting portfolio companies. Previously she was at Kite, where she and her team played a key role in generating non-clinical data packages for […]
Christopher Wilfong
Christopher Wilfong is a Corporate Development and Strategy Advisor to IconOVir Bio. In addition, Mr. Wilfong is an Operating Partner at Two River Consulting, LLC, where he has been a co-founder and held senior leadership roles in multiple Two River portfolio companies, including Kite Pharma, Inc., Kronos Bio, Inc., and Neogene Therapeutics, Inc. Prior to […]
Sean Algeo, CPA
Sean Algeo is the Treasurer and Corporate Controller of IconOVir Bio. He also serves as Chief Financial Officer at Two River Consulting, LLC, where he is responsible for all financial and accounting activities of Two River and certain of its portfolio companies. Prior to joining Two River in 2018, Mr. Algeo was a Senior Manager […]
David Tanen
David Tanen is a co-founder of Two River, LLC, a life science consulting and investment firm, where he has served as a partner since its inception in September 2004. He has also served as an advisor to Vida Ventures, a life science venture capital firm since November 2018. Mr. Tanen was a co-founder of Kite […]
Joshua Kazam
Joshua Kazam is a co-founder and director of IconOVir Bio. Josh is also a co-founder and director of Kronos Bio, Inc. (KRON), and Allogene Therapeutics, Inc. (ALLO), and is a co-founder and Partner of Two River, where he has served as partner since its inception in 2004. He is a co-founder and partner of Vida […]
Frank McCormick, Ph.D., FRS, DSc (Hon)
Frank McCormick, PhD, is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice […]
Arie Belldegrun, M.D.
Arie Belldegrun, M.D., is a co-founder and Director of IconOVir Bio. He is also Executive Chairman and co-founder of Allogene Therapeutics, Inc. (ALLO), a clinical stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. A visionary entrepreneur, Arie founded Kite Pharma, a biopharmaceutical company […]
Mark Chao, M.D., Ph.D.
Dr. Chao is currently the Chief Medical Officer of Scorpion Therapeutics and has over 20 years of experience in oncology research. He was most recently co-founder and CEO of TenSixteen Bio, a precision genomics therapeutics company. Previously, he served as VP in oncology clinical research at Gilead Sciences focused on early and late-stage clinical development. Prior to that, […]
Mark McCamish, M.D., Ph.D.
Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Previously he was President and Chief Executive Officer of Forty Seven, Inc. He led Forty Seven, Inc. during critical phases of clinical development to help patients defeat their cancer. This included growing from a valuation of $169 million as a private company through a […]